Shifting First-Line Strategy: Inavolisib Shows OS, PFS Gains in INAVO120 Trial
Can We Improve Second-Line Outcomes in ESR1-Mutated mBC? Insights From ADELA
Dr. Rebecca Shatsky on the Top Breakthroughs in TNBC at ASCO 2025